Vetoquinol: down slightly after quarterly sales figures
Sales of essential products rose by 9% to €81 million (+12.2% at constant exchange rates), driven by the development of the existing portfolio and the ongoing launches of Felpreva in Europe and Simplera in the USA.
In a global animal health market still driven by prices, we are continuing to launch and ramp up our new essentials, which will drive our long-term strategy", comments CEO Matthieu Frechin.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction